Twist Bioscience Corporation (TWST) Stock

Twist Bioscience Corporation operates at the cutting edge of synthetic biology, specializing in the manufacturing and distribution of synthetic DNA-based products. Utilizing a pioneering DNA synthesis platform, the company facilitates the creation of synthetic DNA through an innovative process of writing genetic code on a silicon chip. This platform supports a diverse range of applications, from synthetic genes and tools for sample preparation to antibody libraries crucial for drug discovery and development. Additionally, Twist Bioscience is recognized for its breakthroughs in DNA as a digital data storage medium, offering unprecedented potential for information storage solutions.

The company has established strategic collaborations with prominent entities in the biotechnology sector, underscoring its commitment to advancing genetic research and applications. These partnerships include Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., focusing on the development of advanced sequencing tools and innovative genetic solutions.

Twist Bioscience further solidifies its position through a significant research collaboration with Boehringer Ingelheim International GmbH. This collaboration leverages Twist's proprietary antibody libraries to discover therapeutic antibodies targeting multiple disease targets, further enhancing its role in therapeutic innovation.

Founded in 2013 and headquartered in South San Francisco, California, Twist Bioscience continues to drive forward the frontiers of synthetic biology, pioneering new applications and solutions that redefine possibilities in genetic research and biotechnology.